Autopsy report · NCT03973333

Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab

“Study withdrawn by Sponsor”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1, Phase 2

Sponsor

Immunocore Ltd

Sponsor type

Industry

Conditions

Select Advanced Solid Tumors

Interventions

IMC-C103C; Atezolizumab; IMC-C103C

Participants

0

Sites

19

Countries

Spain, United Kingdom, United States

Trials that died the same way

• A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy
  “Study was withdrawn per sponsor decision” (94% match in meaning)
• Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial
  “Sponsor withdrew the study” (94% match in meaning)
• EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis
  “Study Withdrawn by Sponsor prior to Enrollment.” (93% match in meaning)
• NRX-1074 in Early Course Schizophrenia
  “The study was withdrawn by the sponsor.” (90% match in meaning)
• Effects of AffronEye®/ Crocuvis+® on Dry Eye Syndrome
  “Study withdrawn prior to enrollment due to sponsor decision” (90% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.